First-line Immunotherapy in Metastatic Urothelial Carcinoma

被引：3

作者：

Ghatalia, Pooja ^{[1
]}

Zibelman, Matthew ^{[1
]}

Geynisman, Daniel M. ^{[1
]}

Plimack, Elizabeth R. ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

来源：

EUROPEAN UROLOGY FOCUS | 2020年 / 6卷 / 01期

关键词：

CISPLATIN; CHEMOTHERAPY; ATEZOLIZUMAB; METHOTREXATE; VINBLASTINE; MULTICENTER; DOXORUBICIN; TRIAL;

D O I：

10.1016/j.euf.2019.04.015

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：45 / 47

页数：3

共 12 条

[1] [Anonymous], 2018, SEER stat fact sheets: Melanoma of the skin
[2] [Anonymous], 2018, ACUTE MYELOID LEUKEM
[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, Arjun V.
Galsky, Matthew D.
Rosenberg, Jonathan E.
Powles, Thomas
Petrylak, Daniel P.
Bellmunt, Joaquim
Loriot, Yohann
Necchi, Andrea
Hoffman-Censits, Jean
Perez-Gracia, Jose Luis
Dawson, Nancy A.
van der Heijden, Michiel S.
Dreicer, Robert
Srinivas, Sandy
Retz, Margitta M.
Joseph, Richard W.
Drakaki, Alexandra
Vaishampayan, Ulka N.
Sridhar, Srikala S.
Quinn, David I.
Duran, Ignacio
Shaffer, David R.
Eigl, Bernhard J.
Grivas, Petros D.
Yu, Evan Y.
Li, Shi
Kadel, Edward E., III
Boyd, Zachary
Bourgon, Richard
Hegde, Priti S.
Mariathasan, Sanjeev
Thastrom, AnnChristine
Abidoye, Oyewale O.
Fine, Gregg D.
Bajorin, Dean F.
[J]. LANCET, 2017, 389 (10064) : 67 - 76
[4] Pembrolizumab for Advanced Urothelial Carcinoma
Liang, Fei
Zhu, Ji
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23) : 2302 - 2302
[5] Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
Dash, Atreya
Galsky, Matthew D.
Vickers, Andrew J.
Serio, Angel M.
Koppie, Theresa M.
Dalbagni, Guido
Bochner, Bernard H.
[J]. CANCER, 2006, 107 (03) : 506 - 513
[6] Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy
Galsky, Matthew D.
Hahn, Noah M.
Rosenberg, Jonathan
Sonpavde, Guru
Hutson, Thomas
Oh, William K.
Dreicer, Robert
Vogelzang, Nicholas
Sternberg, Cora N.
Bajorin, Dean F.
Bellmunt, Joaquim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2432 - 2438
[7] Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
O'Donnell, Peter H.
Grivas, Petros
Balar, Arjun Vasant
Bellmunt, Joaquim
Vuky, Jacqueline
Powles, Thomas
Plimack, Elizabeth R.
Hahn, Noah M.
De Wit, Ronald
Pang, Lei
Savage, Mary J.
Lunceford, Jared K.
Keefe, Stephen Michael
Bajorin, Dean F.
Castellano, Daniel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Powles, Thomas
Duran, Ignacio
van der Heijden, Michiel S.
Loriot, Yohann
Vogelzang, Nicholas J.
De Giorgi, Ugo
Oudard, Stephane
Retz, Margitta M.
Castellano, Daniel
Bamias, Aristotelis
Flechon, Aude
Gravis, Gwenaelle
Hussain, Syed
Takano, Toshimi
Leng, Ning
Kadel, Edward E., III
Banchereau, Romain
Hegde, Priti S.
Mariathasan, Sanjeev
Cui, Na
Shen, Xiaodong
Derleth, Christina L.
Green, Marjorie C.
Ravaud, Alain
[J]. LANCET, 2018, 391 (10122) : 748 - 757
[9] Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924
Sternberg, CN
de Mulder, PHM
Schornagel, JH
Théodore, C
Fossa, SD
van Oosterom, AT
Witjes, F
Spina, M
van Groeningen, CJ
de Balincourt, C
Collette, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2638 - 2646
[10] U.S. Food and Drug Administration, FDA AL HLTH CAR PROF

← 1 2 →